These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27250932)

  • 21. Otorhinolaryngological Toxicities of New Drugs in Oncology.
    Hartl DM; Morel D; Saavedra E; Massard C; Rinaldo A; Saba NF; Ferlito A; Soria JC
    Adv Ther; 2017 Apr; 34(4):866-894. PubMed ID: 28315206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic protein kinase inhibitors.
    Grant SK
    Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody Drug Conjugates: Nonclinical Safety Considerations.
    Hinrichs MJ; Dixit R
    AAPS J; 2015 Sep; 17(5):1055-64. PubMed ID: 26024656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of clinical risks by analysis of preclinical and clinical adverse events.
    Clark M
    J Biomed Inform; 2015 Apr; 54():167-73. PubMed ID: 25746390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.
    Rosenfeldt H; Kropp T; Benson K; Ricci MS; McGuinn WD; Verbois SL
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):125-33. PubMed ID: 20045015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database.
    Monticello TM; Jones TW; Dambach DM; Potter DM; Bolt MW; Liu M; Keller DA; Hart TK; Kadambi VJ
    Toxicol Appl Pharmacol; 2017 Nov; 334():100-109. PubMed ID: 28893587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive toxicology approaches for small molecule oncology drugs.
    Maziasz T; Kadambi VJ; Silverman L; Fedyk E; Alden CL
    Toxicol Pathol; 2010 Jan; 38(1):148-64. PubMed ID: 20075108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An FDA oncology analysis of antibody-drug conjugates.
    Saber H; Leighton JK
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):444-52. PubMed ID: 25661711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy.
    Mladosievicova B; Carter A; Kristova V
    Neoplasma; 2007; 54(3):181-8. PubMed ID: 17447847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
    Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
    Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fusion of nonclinical and clinical data to predict human drug safety.
    Johnson DE
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):185-95. PubMed ID: 23473595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.